Mizuho analyst Graig Suvannavejh raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $101 from $100 and keeps an Outperform rating on the shares after the company announced its Chinese partner, Grand Pharma, received approval to commercialize TP-03 for the treatment of Demodex blepharitis in the Greater China region. The approval came a bit earlier than expected, says the firm, which remains confident in Tarsus’ execution on the U.S. Xdemvy launch and sees a favorable risk/reward with shares down 22% year-to-date.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval
- Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
- Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer
- Tarsus Pharmaceuticals price target raised to $90 from $87 at Guggenheim
- Tarsus Pharmaceuticals rises 11.6%